Xenetic Biosciences, Inc. (XBIO) — SEC Filings
Xenetic Biosciences, Inc. (XBIO) — 29 SEC filings. Latest: 8-K (Dec 11, 2025). Includes 16 8-K, 5 10-Q, 3 10-K/A.
View Xenetic Biosciences, Inc. on SEC EDGAR
Overview
Xenetic Biosciences, Inc. (XBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: On December 11, 2025, Xenetic Biosciences, Inc. filed an 8-K report. The filing primarily serves as a notification of events and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 2 mixed. The dominant filing sentiment for Xenetic Biosciences, Inc. is neutral.
Filing Type Overview
Xenetic Biosciences, Inc. (XBIO) has filed 16 8-K, 5 10-Q, 1 DEF 14A, 3 10-K/A, 1 8-K/A, 2 10-K, 1 SC 13D/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of XBIO's 28 recent filings, 3 were flagged as high-risk, 12 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,026,957 |
| Net Income | $(509,940) |
| EPS | $(0.33) |
| Debt-to-Equity | N/A |
| Cash Position | $4,121,599 |
| Operating Margin | N/A |
| Total Assets | $5,067,960 |
| Total Debt | $0 |
Key Executives
- Board of Directors
- Chief Executive Officer
- Grigory Borisenko
- Firdaus Jal Dastoor
- Dmitry Genkin
- Roger Kornberg
- Moshe Mizrahy
- Alexey Vinogradov
- James Parslow
- Dr. Jeffrey S. Henderson
- Mr. David L. Dawson
- Dr. Curtis R. Selby
- Mr. Michael J. McLellan
- Dr. Jeffrey M. Hackman
- Dr. David M. Goldenberg
Industry Context
The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies often rely on partnerships and licensing agreements for revenue, as seen with XBIO's royalty income from Takeda. The industry is competitive, with success often hinging on the efficacy and market adoption of novel therapies.
Top Tags
filing (4) · amendment (4) · 8-k (3) · operations (3) · 10-K (3) · financial-condition (3) · Xenetic Biosciences (3) · regulatory-filing (2) · Biotechnology (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Royalty revenue for Q3 2025 | $1,026,957 | Increased by 67.2% from $614,243 in Q3 2024 |
| Total revenue for nine months ended Sep 30, 2025 | $2,210,115 | Increased by 19.4% from $1,851,464 in the prior year period |
| Net loss for Q3 2025 | $(509,940) | Worsened from $(436,671) in Q3 2024 |
| Net loss for nine months ended Sep 30, 2025 | $(2,101,784) | Improved from $(2,905,754) in the prior year period |
| Cash as of Sep 30, 2025 | $4,121,599 | Decreased from $6,165,568 at Dec 31, 2024 |
| Research and development expenses for Q3 2025 | $756,482 | Increased by 105.5% from $367,985 in Q3 2024 |
| Capital raised in underwritten offering | $3.9 million | Subsequent to quarter end, providing short-term liquidity |
| Outstanding shares of common stock | 2,291,056 | As of November 7, 2025 |
| Shares of common stock outstanding | 2,277,139 | Entitled to vote as of October 15, 2025 |
| Annual Meeting Date | December 11, 2025 | Date of the virtual Annual Meeting of Stockholders |
| Record Date | October 15, 2025 | Date for determining stockholders entitled to vote |
| Number of Director Nominees | 6 | Directors proposed for election |
| Revenue | $0 | No revenue for Q2 2025 or YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $2.5M | Increased by 38.9% from $1.8M in Q2 2024, showing rising operational costs. |
| Net Loss (YTD 2025) | $4.9M | Increased by 40% from $3.5M in YTD 2024, reflecting higher R&D and G&A expenses. |
Forward-Looking Statements
- {"claim":"Xenetic Biosciences will use the capital raised for research and development of its pharmaceutical preparations.","entity":"Xenetic Biosciences, Inc.","targetDate":"2025-02-12","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Xenetic Biosciences, Inc. (XBIO)?
Xenetic Biosciences, Inc. has 29 recent SEC filings from Feb 2024 to Dec 2025, including 16 8-K, 5 10-Q, 3 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XBIO filings?
Across 29 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Xenetic Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xenetic Biosciences, Inc. (XBIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xenetic Biosciences, Inc.?
Key financial highlights from Xenetic Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XBIO?
The investment thesis for XBIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xenetic Biosciences, Inc.?
Key executives identified across Xenetic Biosciences, Inc.'s filings include Board of Directors, Chief Executive Officer, Grigory Borisenko, Firdaus Jal Dastoor, Dmitry Genkin and 14 others.
What are the main risk factors for Xenetic Biosciences, Inc. stock?
Of XBIO's 28 assessed filings, 3 were flagged high-risk, 12 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Xenetic Biosciences, Inc.?
Recent forward-looking statements from Xenetic Biosciences, Inc. include guidance on {"claim":"Xenetic Biosciences will use the capital raised for research and development of its pharmaceutical preparation.